Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Pancreatic cancer stories

Oct 15, 2026

Revolution Medicines wins EU panel backing for pancreatic cancer drug Rasonque

The European Medicines Agency's advisory committee recommended approval of Revolution Medicines' Rasonque for adults with metastatic pancreatic cancer that has progressed after at least one prior therapy.

Oct 15, 2026·2 sources
00
Oct 14, 2026

Verastem raises $250M as KRAS inhibitor shows promise in pancreatic cancer

Verastem Oncology announced encouraging early results for its KRAS G12D inhibitor in pancreatic cancer patients alongside a $250 million fundraise and CEO departure, positioning itself as a competitor to Revolution Medicines in next-generation KRAS treatments.

Oct 14, 2026·3 sources
00
May 8, 2026

AI Model Detects Pancreatic Cancer Up to 3 Years Earlier Than Doctors in Early Test

A new AI tool successfully identified early signs of pancreatic cancer in CT scans that human doctors would miss, potentially enabling detection up to three years before conventional diagnosis in initial testing.

May 8, 2026·1 source
00
Apr 29, 2026

Breakthrough Study Shows AI Can Predict Pancreatic Cancer Years in Advance

New study shows artificial intelligence can identify early signs of pancreatic cancer years before diagnosis, offering potential for earlier intervention and improved survival outcomes.

Apr 29, 2026·3 sources
00
Apr 22, 2026

Revolution Medicines Presents Additional Strong Data on KRAS-Targeting Pancreatic Cancer Drug

Revolution Medicines presented new positive clinical trial data at AACR for its KRAS-targeting drug in pancreatic cancer patients, building on previously reported breakthrough survival results and expanding evidence for a novel class of treatments beyond current KRAS inhibitors.

Apr 22, 2026·3 sources
00

Top claims

  • ▪In a late-stage clinical trial of 500 patients, Revolution Medicines' drug Rasonque extended median survival to 12.4 months compared to 6.7 months for patients receiving chemotherapy
  • ▪Revolution Medicines' final-stage trial showed Rasonque nearly doubled the standard survival time for patients with aggressive pancreatic cancer
  • ▪The European Medicines Agency panel's October 15, 2026 recommendation moves Revolution Medicines' pancreatic cancer treatment Rasonque closer to market authorization across the 27-nation European Union

Topics

Cancer treatment breakthroughsCancer TypesCancer & OncologyClinical trialsDrug Policy, Pricing & ApprovalPublic healthcareComputer VisionAI in healthcareDrug Approval and Clinical TrialsAIAI research & benchmarksArtificial intelligenceVertical AI applicationsPrecision medicineCancer Treatment & Therapies

Related entities

CT Scan